Close
What would you like to look for?
Site search
Search filters

Management Buy-Out of Roventa-Henex

6 September 2022

The management acquired 60% of the share capital of Roventa-Henex SA, a leading manufacturer of quality Swiss Made Private Label watches founded in 1959. Munich-based Findos Investor GmbH retains the remaining 40% of the share capital.

QoQa finances its craft brewery through a security token offering

29 July 2022

QoQa Brew SA, a subsidiary of QoQa Services SA, financed its craft brewery through a security token offering.

Mosanna Therapeutics AG closes Seed Financing Round

25 July 2022

Mosanna Therapeutics AG, a Basel-based biotechnology company developing the advanced small molecule MOS118 (formerly know as AVE0118) for the treatment of metabolic obstructive sleep apnea, closes a Seed Financing Round led by Forty51 Ventures.

ImmunOs Therapeutics AG to raise CHF 74m Series B financing

7 June 2022

ImmunOs Therapeutics AG has agreed to a CHF 74 million Series B financing led by incoming co-lead investors Samsara Biocapital, Lightspeed Venture Partners and Gimv, corner-stoned by GL Capital, Mission BioCapital, Peak 6 Strategic Capital and Fiscus Financial

Engimmune Therapeutics AG raises CHF 15.5m in a Seed Financing

20 May 2022

Engimmune Therapeutics AG, a biotech company based in Basel developing novel T-cell receptor (TCR)-based therapeutics, closed a CHF 15.5m seed financing round.

Cimeio Therapeutics announced its launch and financing

20 May 2022

Cimeio Therapeutics announced its launch including a USD 50m Series A commitment made by Versant Ventures.

Gilde Buy Out Partners joins forces with Founders and Management of MBK

15 February 2022

Funds advised by Gilde Buy Out Partners, a leading European private equity investor, completed the investment in MBK Fincom ("MBK" or the "Company"), alongside the founders and management which are reinvesting in the business....

NEMIS Technologies AG closed a CHF 7.75m Series A Financing Round

10 February 2022

NEMIS Technologies AG closed a CHF 7.75m Series A financing round with the participation of both institutional and private investors.

Anaveon to raise CHF 110m in oversubscribed Series B financing

17 December 2021

Anaveon AG ("Anaveon"), a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 110m Series B financing.

Orell Füssli Thalia AG acquires a stake in Evrlearn AG

10 December 2021

Orell Füssli Thalia AG acquired a stake as Lead Investor in the digital community platform Evrlearn AG.